Product Acquisitions and Return of Product Rights - Change in Consideration, Vibativ (Details) - USD ($) |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Loss Contingency Accrual [Roll Forward] | ||
| Change in fair value of contingent consideration included in operating expenses | $ (228,965) | $ 44,976 |
| Product Assets And Global Rights - Vibativ | ||
| Loss Contingency Accrual [Roll Forward] | ||
| Beginning balance | 3,630,598 | |
| Cash payment of royalty during the period | (554,410) | |
| Change in fair value of contingent consideration included in operating expenses | (107,096) | |
| Contingent consideration earned and accrued in operating expenses | 359,640 | |
| Ending balance | $ 3,328,732 | |